KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Change in Inventory (2016 - 2025)

Travere Therapeutics' Change in Inventory history spans 12 years, with the latest figure at -$1.2 million for Q4 2025.

  • For Q4 2025, Change in Inventory fell 512.98% year-over-year to -$1.2 million; the TTM value through Dec 2025 reached -$5.0 million, down 233.02%, while the annual FY2025 figure was -$5.0 million, 233.02% down from the prior year.
  • Change in Inventory reached -$1.2 million in Q4 2025 per TVTX's latest filing, down from -$194000.0 in the prior quarter.
  • In the past five years, Change in Inventory ranged from a high of $22.4 million in Q4 2023 to a low of -$3.7 million in Q1 2025.
  • Average Change in Inventory over 5 years is $2.0 million, with a median of $201500.0 recorded in 2022.
  • Peak YoY movement for Change in Inventory: skyrocketed 59028.95% in 2023, then crashed 512.98% in 2025.
  • A 5-year view of Change in Inventory shows it stood at -$497000.0 in 2021, then soared by 92.35% to -$38000.0 in 2022, then surged by 59028.95% to $22.4 million in 2023, then crashed by 98.73% to $285000.0 in 2024, then plummeted by 512.98% to -$1.2 million in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Change in Inventory are -$1.2 million (Q4 2025), -$194000.0 (Q3 2025), and $19000.0 (Q2 2025).